Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from BML ( (JP:4694) ).
BML, Inc. reported solid results for the fiscal year ended March 31, 2026, with net sales rising 4.9% to ¥150.3 billion and profit attributable to owners of parent climbing 23.7% to ¥7.7 billion, lifting basic earnings per share to ¥203.54. The group maintained a strong balance sheet with an equity ratio of 69.7%, generated higher operating cash flow, and kept cash and equivalents above ¥64.6 billion.
The company raised its full-year dividend to ¥125 per share for fiscal 2025 while holding the dividend payout ratio to 61.4%, and it plans to keep the dividend at the same level in fiscal 2026. For the year to March 2027, BML forecasts modest sales and profit growth at the operating level but expects a 9.7% decline in profit attributable to owners of parent, signaling a cautious outlook despite robust shareholder returns and a still-solid financial position.
More about BML
BML, Inc., listed on the Tokyo Stock Exchange, operates in the Japanese healthcare and diagnostics sector, providing clinical testing and related medical laboratory services. The company focuses on stable, recurring demand from medical institutions and aims to balance growth investments with shareholder returns in a defensively positioned market.
Average Trading Volume: 80,210
Technical Sentiment Signal: Buy
Current Market Cap: Yen143B
For detailed information about 4694 stock, go to TipRanks’ Stock Analysis page.